Company Description
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers in Malaysia and Singapore.
Its lead product candidate is CTM-N2D, which is in Phase I clinical trials comprising expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity.
The company is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers.
It has research collaboration agreement with Sengkang General Hospital Pte Ltd to establish proof-of-concept use of an injectable cartilage regeneration therapy that has been developed with donor-sourced, (allogeneic) umbilical cord-derived mesenchymal stem cells (UC-MSCs) to treat cartilage injury.
The company was incorporated in 2018 and is headquartered in Singapore.
| Country | Singapore |
| Founded | 2018 |
| IPO Date | Apr 14, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 27 |
| CEO | Chee Kong Choo |
Contact Details
Address: #08-22 One Commonwealth 1 Commonwealth Lane, U0 149544 Singapore | |
| Phone | 603824911 |
| Website | w2.cytomed.sg |
Stock Details
| Ticker Symbol | GDTC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001873093 |
| ISIN Number | SGXZ17669631 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Chee Kong Choo | Executive Chairman |
| Dr. Wee Kiat Tan Ph.D. | Chief Operating Officer and Director |
| Dr. Jieming Zeng | Chief Scientific and Medical Officer and Director |
| Dr. Tien Wee Luk | Chief Clinical Officer and Director |
| Yvonne Goh | Chief Financial Officer |
| Yoong Ying Tan | Chief Corporate Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 18, 2024 | 6-K | Report of foreign issuer |
| Mar 4, 2024 | 6-K | Report of foreign issuer |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jan 29, 2024 | 6-K | Report of foreign issuer |
| Nov 17, 2023 | 6-K | Report of foreign issuer |
| Sep 25, 2023 | 6-K | Report of foreign issuer |
| Aug 1, 2023 | 6-K | Report of foreign issuer |